2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 935

Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2
Abstract Number: 2095

Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Abstract Number: 996

Neutralizing Effect of Anti-Infliximab Antibodies on Infliximab-Stimulated Human Coronary Artery Endothelial Cells
Abstract Number: 1456

Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis
Abstract Number: 2116

Neutrophil Extracellular Trap Formation Is Dependent on Disease Activity in Systemic Lupus Erythematosus: Determination Using a Flow Cytometry-Based Assay
Abstract Number: 766

Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
Abstract Number: 1003

Neutrophil Response to Ultraviolet Light in Normal and Lupus Conditions
Abstract Number: 2775

Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
Abstract Number: 1916

Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
Abstract Number: 923

Neutrophils from Children with Systemic JIA Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
Abstract Number: L01

New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Abstract Number: 981

New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis
Abstract Number: 845

New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
Abstract Number: 2916

New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Abstract Number: 1795

New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].